Radiotherapy Market: Growth Trends, Drivers, and Future Outlook
The global radiotherapy market is on a steady growth trajectory as cancer incidence rises worldwide and healthcare systems increasingly turn to advanced radiation-based treatments. Radiotherapy, which uses high-energy radiation to destroy tumor cells and shrink tumors, has become a cornerstone of modern oncology, offering a non-invasive alternative to surgery for a wide range of cancers. The market was valued at USD 6.05 billion in 2025 and is projected to grow from USD 6.39 billion in 2026 to USD 10.41 billion by 2034, registering a CAGR of 6.3% during the forecast period, according to Fortune Business Insight. North America led the industry with a 42.98% market share in 2025, according to Fortune Business Insight.
Rising Cancer Burden Fuels Demand
The single biggest force propelling this market is the growing global cancer burden. As the number of patients diagnosed with prostate, lung, breast, and gynecological cancers continues to climb, hospitals and dedicated radiotherapy centers are scaling up their treatment capacity. For instance, approximately 226,650 new cases of lung cancer were reported in the U.S. in 2025, according to Fortune Business Insight, citing American Cancer Society statistics. Similarly, around 1.5 million new cases of prostate cancer were reported globally in 2022, according to Fortune Business Insight.
This expanding patient pool, combined with continuous innovation in radiation therapy systems, is driving adoption across healthcare settings. Patients and clinicians alike are increasingly favoring non-invasive treatment approaches, which has further strengthened the case for radiotherapy over more invasive surgical interventions. Major industry players such as Elekta, GE Healthcare, and Siemens Healthineers AG are capitalizing on this demand through aggressive R&D investment, new product launches, and a steady stream of mergers and acquisitions, according to Fortune Business Insight.
Market Segmentation: Hardware Leads, Software Gains Pace
The market is broadly segmented by product type into hardware and software. The hardware segment, comprising instruments such as linear accelerators (LINACs), proton therapy systems, and carbon ion therapy systems, held the largest share in 2025, according to Fortune Business Insight. This dominance reflects the ongoing global upgrade cycle for advanced radiation delivery equipment. Meanwhile, the software segment, encompassing treatment planning and workflow optimization tools, is expected to grow at a faster CAGR of 6.9% over the forecast period, according to Fortune Business Insight, as providers lean on digital tools to improve precision and efficiency.
By type, external beam radiotherapy (EBRT) remains the dominant treatment modality and is anticipated to account for 77.6% of the market in 2026, according to Fortune Business Insight. Its broad applicability across cancer types, improved safety profile, and expanding installed base of LINACs, estimated at roughly 14,000 units globally, according to Fortune Business Insight, continue to support its leadership position. Systemic radiotherapy, though a smaller segment today, is projected to be the fastest-growing category, expanding at a CAGR of 9.3% through the forecast period, according to Fortune Business Insight.
In terms of application, breast cancer accounted for the largest share of the market in 2025 at 25.9%, according to Fortune Business Insight, driven by the roughly 2.3 million women diagnosed with breast cancer globally in 2022. Lung cancer applications are expected to be the fastest-growing segment, with a projected growth rate of 7.2% during the forecast period, according to Fortune Business Insight. By end user, hospitals and clinics dominated the market, holding an estimated 71.9% share in 2025, according to Fortune Business Insight, while radiotherapy centers are projected to grow at a CAGR of 7.0%.
Regional Dynamics
North America remains the largest regional market, valued at USD 6.05 billion in 2025 with the U.S. market alone estimated at USD 2.35 billion, according to Fortune Business Insight. The region’s leadership stems from advanced technology adoption, strong reimbursement frameworks, and a high prevalence of cancer, including an estimated 230,125 prostate cancer patients in the U.S. in 2022, according to Fortune Business Insight.
Europe follows as the second-largest market, valued at USD 1.74 billion in 2025 and projected to grow at a CAGR of 6.2%, according to Fortune Business Insight. Growth in the region is being driven by high adoption of external beam and brachytherapy technologies, centralized cancer centers, and cross-border patient referrals. Within Europe, Germany led individual country valuations at USD 0.42 billion, followed by France at USD 0.32 billion and the U.K. at USD 0.25 billion, according to Fortune Business Insight.
Asia Pacific ranked as the third-largest regional market, reaching USD 1.27 billion in 2025, according to Fortune Business Insight, supported by expanding healthcare infrastructure in China, Japan, South Korea, and India. China led the region at USD 0.56 billion, while India stood at USD 0.16 billion, according to Fortune Business Insight. Latin America and the Middle East & Africa, while smaller markets, are also expected to see moderate growth, with Latin America valued at USD 0.25 billion and the GCC region at USD 0.09 billion in 2025, according to Fortune Business Insight.
Opportunities and Challenges
Proton therapy adoption represents one of the most promising growth avenues for the market, owing to its reduced toxicity and superior dose distribution compared with conventional radiation methods. According to Fortune Business Insight, there are approximately 125 active particle therapy centers operating worldwide as of 2025, reflecting the accelerating global investment in precision oncology infrastructure.
However, cost remains a significant barrier to broader adoption. Establishing a proton therapy facility with three to four treatment rooms can cost between USD 100 million and USD 200 million, according to Fortune Business Insight. This steep capital requirement, combined with ongoing regulatory compliance and software upgrade costs, limits penetration in developing economies such as China and Mexico. Compounding this challenge, an estimated 58 countries, mostly low- and low-middle-income nations, have no radiotherapy facilities at all, according to Fortune Business Insight, underscoring a persistent global access gap.
Technology Trends Shaping the Future
Technological innovation continues to redefine the competitive landscape. Advancements such as adaptive radiotherapy, magnetic resonance-guided therapy, real-time tumor tracking, and AI-integrated workflows are enabling more accurate and personalized treatment delivery. In a notable recent development, Accuray Incorporated launched its all-in-one Stellar Solution in September 2025 to strengthen its U.S. product portfolio, according to Fortune Business Insight. Other key players, including Hitachi High-Tech Corporation, Canon Medical Systems Corporation, Brainlab SE, and IBA Worldwide, continue to expand their offerings through new product launches and strategic collaborations.
As cancer prevalence continues to rise globally and healthcare systems prioritize precision, non-invasive treatment options, the radiotherapy market is well-positioned for sustained expansion through 2034, even as cost and access challenges persist in emerging economies.
What’s Driving Japan’s Market? Discover the Latest “Radiotherapy Market” Insights